Mirati Therapeutics
9363 Towne Centre Drive
Suite 200
San Diego
California
92121
United States
Tel: 858-535-2075
184 articles with Mirati Therapeutics
-
Mirati Therapeutics to Take Part in the 42nd Annual Goldman Sachs Global Healthcare Conference
6/2/2021
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference, which will be webcast on June 9.
-
Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
6/1/2021
- Zai Lab obtains the right to develop and exclusively commercialize adagrasib in China, Hong Kong, Macau and Taiwan - Mirati to receive an upfront payment of $65 million, up to approximately $273 million in potential milestone payments and high-teen- to low-twenties-percent tiered royalties - Agreement will accelerate enrollment in key global, registration-enabling clinical trials investigating adagrasib in patients with KRAS G12C mutations
-
Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates
5/6/2021
Initiated potentially registration-enabling trials evaluating our investigational KRASG12C inhibitor, adagrasib, in lung and colorectal cancers, as monotherapy and with other agents
-
Stand Up To Cancer Announces $4 Million Grant From Mirati Therapeutics To Support Research On KRAS Mutant Cancers
4/19/2021
Stand Up To Cancer® and Mirati Therapeutics Inc. – a late-stage targeted oncology company – announced that Mirati will contribute a $4 million grant to SU2C to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst® program.
-
Mirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models
4/10/2021
Internally discovered PRMT5 program represents a potential first-in-class approach to specifically target MTAP-deleted tumors Anticipate filing an Investigational New Drug application in the first half of 2022
-
Mirati Therapeutics Board Elects Shalini Sharp as New Independent Director
3/31/2021
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced its Board of Directors has elected a new independent director, Ms. Shalini Sharp .
-
Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021
3/10/2021
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced it will present initial preclinical data on the Company's synthetic lethal PRMT5 inhibitor during a late-breaking minisymposium at the American Association for Cancer Research (AACR) Virtual Annual Meeting taking place April 10-15, 2021.
-
Mirati Therapeutics To Present At Upcoming Healthcare Conferences - Feb 18, 2021
2/18/2021
Mirati Therapeutics, Inc., a late-stage targeted oncology company, will participate in two upcoming healthcare conferences.
-
MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors
2/10/2021
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational small molecule, potent and selective KRAS inhibitors
-
Mirati Therapeutics To Present At Guggenheim Healthcare Talks 2021 Oncology Days
2/4/2021
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced they will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Days on Thursday, February 11 th at 9:00 a.m. ET / 6:00 a.m. PT
-
Mirati Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare Conference
1/4/2021
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 11 th at 12:40 p.m. PST / 3:40 p.m. EST . Charles M. Baum , M.D., Ph.D., Mirati's President and Chief Executive Officer will present at the con
-
Mirati Therapeutics To Participate In The 2020 Evercore ISI HealthCONx Conference
11/23/2020
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 2020 Evercore ISI HealthCONx Conference on Tuesday, December 1st at 8:20 a.m. PT/11:20 a.m. ET. Dan Faga, Executive Vice President and Chief Operating Officer, will represent Mirati at the event.
-
Mirati Therapeutics To Participate In The 29th Annual Credit Suisse Virtual Healthcare Conference
11/5/2020
Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced they will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Thursday, November 12, 2020 at 9:30 a.m. PT/12:30 p.m. ET.
-
Mirati Therapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights
11/4/2020
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2020 and recent business highlights.
-
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares - Oct 30, 2020
10/30/2020
Mirati Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 4,985,706 shares of its common stock at a public offering price of $202.00 per share, which consists of 4,585,706 shares sold by Mirati and 400,000 shares sold by a selling stockholder.
-
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock - Oct 28, 2020
10/28/2020
Mirati Therapeutics, Inc. announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00 per share, which consists of 3,960,397 shares to be sold by Mirati and 375,000 shares to be sold by a selling stockholder.
-
Mirati Therapeutics Announces Proposed Public Offering of Common Stock - Oct 26, 2020
10/26/2020
Mirati Therapeutics, Inc. announced that it intends to offer and sell in an underwritten public offering $700.0 million of shares of its common stock and a selling stockholder intends to offer 375,000 shares in the offering.
-
Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as well as Initial MRTX1133 Preclinical Data
10/25/2020
45% confirmed ORR and 96% DCR across Phase 1/1b and Phase 2 monotherapy cohorts in patients with advanced NSCLC
-
Mirati Therapeutics To Present Data During The 2020 EORTC-NCI-AACR International Virtual Conference On Molecular Targets And Therapeutics (ENA)
10/15/2020
- Updated adagrasib (MRTX849) clinical data in non-small cell lung cancer (NSCLC) patients will be featured in a plenary session at ENA - Updated adagrasib clinical data in colorectal cancer (CRC) and other KRAS G12C positive solid tumors outside of NSCLC will be presented in a second session at ENA - Mirati to host virtual investor event on October 25th to discuss adagrasib clinical data presented at ENA and provide an update on MRTX1133, the Company's KRAS G12D selective in
-
San Diego-based Mirati Therapeutics, a clinical-stage biotechnology company, is currently developing sitravatinib to address unmet medical needs in cancer care.